AstraZeneca beats profit estimates and maintains outlook
The drugmaker exceeded first-quarter profit expectations and maintained its annual outlook. Strong demand for cancer treatments drove the performance.
Xurve View
Insights:
Xurve View
ASTRAZENECA PLC beat first-quarter sales and profit expectations on Wednesday, April 29, while maintaining its full-year 2026 financial outlook. The results reflect sustained demand for oncology treatments and expanded footprints in the United States and China. Investors view the steady guidance as a sign of resilience against geopolitical volatility and shifting global drug pricing policies.
